Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Diane Flershem

Internal Medicine Arlington Heights, IL Medical Doctor

NPI 1447205869 CMS profile 65496

3405 N Arlington Heights Rd, Arlington Heights, IL 60004

Open in the dashboard

General payments

$16,397

573 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Diane Flershem of Arlington Heights, IL is reported in the CMS Open Payments database as having received $16,397 across 573 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,719 87
2024 General $6,758 92
2023 General $2,285 94
2022 General $1,984 99
2021 General $1,641 88
2020 General $921 43
2019 General $1,089 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Diane Flershem
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Diane Flershem were reported at $1,719. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Diane Flershem Internal Medicine median Middle half National median
2019 $1,089 $159 $48–$570 $163
2020 $921 $119 $33–$402 $114
2021 $1,641 $135 $37–$521 $132
2022 $1,984 $141 $42–$496 $149
2023 $2,285 $149 $45–$519 $160
2024 $6,758 $154 $47–$537 $164
2025 $1,719 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $6,364 63 payments
  2. Novo Nordisk Inc $2,116 101 payments
  3. Amgen Inc. $1,137 72 payments
  4. Pfizer Inc. $1,043 48 payments
  5. Neuronetics, Inc. $783 11 payments
  6. GlaxoSmithKline, LLC. $709 41 payments
  7. AstraZeneca Pharmaceuticals LP $696 41 payments
  8. Merck Sharp & Dohme Corporation $489 37 payments
  9. Lilly USA, LLC $438 22 payments
  10. Janssen Pharmaceuticals, Inc $227 11 payments
  11. Other $2,394 126 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,372 570 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,000 1 payment
  3. Education $25 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,857 87 payments
  2. RYBELSUS $1,549 75 payments
  3. EVENITY $625 35 payments
  4. PREVNAR 20 $524 20 payments
  5. Neurostar TMS Therapy System $477 6 payments
  6. COMIRNATY $473 18 payments
  7. Prolia $465 30 payments
  8. Otezla $444 33 payments
  9. UBRELVY $410 16 payments
  10. Repatha $362 23 payments
  11. Other $9,783 538 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 99 drugs

Part D claims

7,439

Median for Internal Medicine: 777

Drug cost

$398,978

Median for Internal Medicine: $73,373

Branded share of claims

14.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Januvia Sitagliptin Phosphate Brand 42 $44,580
Mounjaro Tirzepatide Brand 30 $39,231
Ozempic Semaglutide Brand 34 $38,030
Rybelsus Semaglutide Brand 18 $28,713
Eliquis Apixaban Brand 30 $26,595
Myrbetriq Mirabegron Brand 48 $26,145
Jardiance Empagliflozin Brand 19 $24,559
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 97 $21,415
Xarelto Rivaroxaban Brand 12 $14,764
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 14 $8,985

The 10 drugs with the highest cost, of 99 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$287,208

Of which drugs: $14,455

Medicare patients

537

Average age 75

Services billed

5,374

464 women, 73 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 48%
Ischemic heart disease 45%
Osteoporosis 35%
Diabetes 18%
Cancer 15%
Atrial fibrillation 13%
Depression 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 26 26 $7,530
Vaccine for influenza for injection into muscle 90653 Office 83 83 $3,254
Sarscv2 vac 30mcg trs-suc im 91320 Office 21 21 $3,031
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 53 406 $353
Influenza vaccine, trivalent, 0.5 ml dosage 90658 Office 12 12 $257

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $186
$186 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $116
$116 — —
RYBELSUS
  • Novo Nordisk Inc $109
$109 18 —
Ozempic
  • Novo Nordisk Inc $109
$109 34 —
UBRELVY
  • AbbVie, Inc. $106
$106 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

573 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record